(AOF) – Transgene announces the collection of 15.3 million dollars (14.0 million euros) following the sale of all of its minority stake in a Chinese biopharmaceutical company. The biotechnology company specializing in viral immunotherapies for the treatment of cancer specifies that following this transaction, the completion of which was expected in mid-2023, it confirms financial visibility until the beginning of 2024.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.